Ontario funding new treatment for advanced-stage prostate cancer
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$0 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*No charge for 4 weeks then price increases to the regular rate of $19.00 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
Monthly Digital Subscription
$4.75/week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $19 plus GST every four weeks. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 14/01/2025 (325 days ago), so information in it may no longer be current.
TORONTO – Ontario’s health minister says the province will now publicly fund a new treatment for advanced-stage prostate cancer.
Health Canada approved Pluvicto in August 2022, but patients have been waiting since then for provincial health plans to announce coverage.
Health Minister Sylvia Jones says Ontario is the first Canadian jurisdiction to publicly fund and administer the treatment.
Ontario says it is working with hospitals to implement Pluvicto as a standard treatment for patients with advanced-stage prostate cancer and it is expected to be available to eligible patients at most of the province’s cancer treatment centres in the next few months.
Pluvicto is a targeted radioligand therapy, a radioactive drug that kills the specific cancer cells, and uses a medical isotope that is produced in Ontario.
Experts say radioligand therapy has lower side-effects than traditional radiation because it minimizes harm to healthy cells.
This report by The Canadian Press was first published Jan. 14, 2025.